After treatment, invasive triple-negative breast cancer can obtain a five-year survival rate of 15% to 80%, which is more related to the stage. Invasive triple-negative breast cancer is one of the types of breast cancer, characterized by negative estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, which is usually more malignant and has a poorer prognosis. Patients with early staging can be treated by surgical excision, and conversely, mainly by non-surgical therapies such as radiotherapy and chemotherapy. After active treatment, the five-year survival rate of patients with triple-negative breast cancer is highly related to the clinical stage, such as 75%~80% in early stage, 50%~60% in middle stage, and only 15% in late stage. It is suggested that patients with breast cancer should consult regular hospitals in time and standardize the treatment under the guidance of doctors in order to improve the survival rate.